by Padma Kumar, Chris Jay, Ila Oxendine, John Nemunaitis, and Phillip Maples
Volume 8, Issue 1 (Spring 2009)
Preliminary studies with a variety of cell-based vaccines suggest target accessibility (potential immunogenicity) to immune-directed approaches in a variety of solid tumors. However, four primary factors limit the generation of effective immune-mediated anticancer activity in therapeutic applications: 1) identifying and/or targeting cancer-associated immunogen(s) (target) in an individual patient; 2) insufficient or inhibited level of antigen-presenting cell (dendritic cell, macrophage) priming and/or presentation; 3) suboptimal T cell activation (potency) and proliferation; and 4) cancer-induced inhibition of the anticancer immune response in both afferent and efferent limbs…
Citation:
Kumar P, Jay C, Oxendine I, Nemunaitis J, Maples P. TAG Xenograft Vaccine: Xenograft-Expanded Autologous Tumor Vaccine Genetically Modified to Express GM-CSF and Block Production of TGFB2. BioProcess J, 2009; 8(1): 30-36. http://dx.doi.org/10.12665/J81.Maples.P1